News

Remidio’s Medios AI shows significant promise in last-mile screening for referable glaucoma

The integrated solution provides an instant report in contexts where there are no specialists

Remidio Innovative Solutions together with Aravind Eye Hospital (AEH), Pondicherry, and Narayana Nethralaya (NN), Bengaluru, announced the results of a landmark clinical trial that can help revolutionise the detection of Referable Glaucoma.

The integrated solution provides an instant report in contexts where there are no specialists. It consists of Remidio’s Fundus on Phone, a retinal imaging device that captures images of the retina without pupil dilation, and Remidio’s Medios Referable Glaucoma AI, an integrated offline AI algorithm that requires no internet for inferencing.

The Medios Referable Glaucoma AI looks beyond the cup-to-disc ratio and detects structural changes in the optic nerve head and surrounding retinal nerve fibre layer. These are critical regions typically assessed by glaucoma specialists during a clinical examination along with an expensive device called Optical Coherence Tomography.

The diagnostic performance of the Medios Referable Glaucoma AI was validated in a first-ever prospective study. It was simultaneously conducted in a tertiary eye care centre, NN, and in last-mile access contexts called Vision Centres (VCs) of AEH.

Among the 237 study subjects at NN, the AI results were compared against the current standard of care, wherein Glaucoma specialists provided the final diagnosis following a comprehensive glaucoma work-up. The AI algorithm demonstrated a high sensitivity of 93.5 per cent (95 per cent CI: 87.1-96.8 per cent ) to detect those with Referable Glaucoma with a specificity of 85.4 per cent (95 per cent CI: 78.3-90.4 per cent). Interestingly, the recall for ‘no glaucoma’ was also high at 94.7 per cent (95 per cent CI: 87.1-97.9 per cent ) with a minimal overcall of normal subjects.

Dr Rohit Shetty, Vice Chairman at Narayana Nethralaya, said,” Our clinical study at NN, shows that AI can bring in much-needed objectivity in glaucoma screening, especially in contexts where there are no specialists. We also see the power of AI to be used in applications as diverse as outreach screening to personalised care.”

Dr R Venkatesh, Chief Medical Officer, Aravind Eye Hospital, said, “AI has helped overcome the challenges often presented with Glaucoma screening in the outreach. The reporting of fundus images has gotten much faster and more reliable with AI. It has great promise in VCs as a clinical decision tool for resident doctors to improve their diagnostic consistency.” 

Dr Divya Rao, Glaucoma specialist and Remidio’s Medical Director & Head of AI, said, “Promising results show that our AI can empower healthcare workers and general ophthalmologists to make an objective screening diagnosis, specifically at centres lacking sophisticated diagnostic equipment.”

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Back to top button
Close
Close